111 related articles for article (PubMed ID: 1576403)
1. Differential activity of bacteriocins and cefotaxime against Serratia marcescens clinical isolate SMG40 and its pigmented variant.
Gratia JP; Crenier L
Zentralbl Bakteriol; 1992 Feb; 276(3):340-6. PubMed ID: 1576403
[TBL] [Abstract][Full Text] [Related]
2. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.
Knothe H; Shah P; Krcmery V; Antal M; Mitsuhashi S
Infection; 1983; 11(6):315-7. PubMed ID: 6321357
[TBL] [Abstract][Full Text] [Related]
3. Comparative activity of N-formimidoyl thienamycin with third generation cephalosporins and ureido penicillins against multiple resistant Serratia marcescens.
Miller MA; LeFrock JL; Vercler MJ
Microbiol Immunol; 1981; 25(11):1119-27. PubMed ID: 6276701
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study of the in vitro activity of dibekacin, piperacillin, cefotaxime and cefuroxime on gram-negative bacteria].
Carlone NA; Cuffini AM; Forno-Pizzoglio M
G Batteriol Virol Immunol; 1983; 76(7-12):239-45. PubMed ID: 6099296
[TBL] [Abstract][Full Text] [Related]
5. [Susceptibility of recent clinical isolates of Pseudomonas aeruginosa and Serratia marcescens to cefotaxime, ceftizoxime, cefmenoxime, latamoxef and cefsulodin in comparison with other beta-lactam antibiotics and aminoglycosides].
Kawakami Y; Okimura Y; Horiuchi N; Kanai M
Jpn J Antibiot; 1982 Sep; 35(9):2314-7. PubMed ID: 6292543
[No Abstract] [Full Text] [Related]
6. Detection of extended broad-spectrum beta-lactamases in Enterobacteriaceae in four French hospitals.
Legrand P; Fournier G; Buré A; Jarlier V; Nicolas MH; Decré D; Duval J; Philippon A
Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):527-9. PubMed ID: 2504594
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic susceptibility of clinical isolates of Serratia marcescens compared with sensitivity to group A (phage tail) bacteriocins.
Traub WH
Chemotherapy; 1978; 24(5):301-13. PubMed ID: 352637
[No Abstract] [Full Text] [Related]
8. Activity of cefuroxime, cefoxitin and amikacin against Serratia marcesens.
Ball P; Gray J
J Antimicrob Chemother; 1979 Jul; 5(4):472-3. PubMed ID: 385581
[No Abstract] [Full Text] [Related]
9. Survey of CTX-M-3 extended-spectrum beta-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan.
Wu LT; Tsou MF; Wu HJ; Chen HE; Chuang YC; Yu WL
Diagn Microbiol Infect Dis; 2004 Jun; 49(2):125-9. PubMed ID: 15183862
[TBL] [Abstract][Full Text] [Related]
10. Studies on group A (phage tail) bacteriocins of Serratia marcescens. VI. Calcium ion-dependent biological activity of subgroup II bacteriocins.
Traub WH; Kleber I
Zentralbl Bakteriol Orig A; 1976 May; 234(4):528-35. PubMed ID: 779358
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of cefamandole, cefoxitin, cefuroxime, and carbenicillin, alone and in combination with aminoglycosides against Serratia marcescens.
Miller MA; Yousuf M; Griffin PS; Bartlett M; Crane JK
Microbiol Immunol; 1979; 23(10):955-64. PubMed ID: 390321
[TBL] [Abstract][Full Text] [Related]
12. Serratia marcescens bacteremia at a medical center in southern Taiwan: high prevalence of cefotaxime resistance.
Shih HI; Lee HC; Lee NY; Chang CM; Wu CJ; Wang LR; Ko NY; Ko WC
J Microbiol Immunol Infect; 2005 Oct; 38(5):350-7. PubMed ID: 16211144
[TBL] [Abstract][Full Text] [Related]
13. Extended-spectrum beta-lactamases conferring resistance to monobactams and oxyimino-cephalosporins in clinical isolates of Serratia marcescens.
Luzzaro F; Pagani L; Porta F; Romero E
J Chemother; 1995 Jun; 7(3):175-8. PubMed ID: 7562009
[TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Verhaegen J; Verbist L
J Antimicrob Chemother; 1998 Mar; 41(3):381-5. PubMed ID: 9578165
[TBL] [Abstract][Full Text] [Related]
15. Short-term bactericidal activity of amoxicillin and cefotaxime against penicillin-susceptible and -resistant pneumococcal strains: an in vitro pharmacodynamic simulation.
Fenoll A; Casal J; Giménez MJ; Jado I; Aguilar L
J Chemother; 2000 Apr; 12(2):124-8. PubMed ID: 10789550
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic susceptibility of Serratia marcescens and Serratia liquefaciens.
Traub WH
Chemotherapy; 2000; 46(5):315-21. PubMed ID: 10965096
[TBL] [Abstract][Full Text] [Related]
17. Bacteriocin (Marcescin) typing of clinical isolates of Serratia marcescens.
Traub WH; Raymond EA; Startsman TS
Appl Microbiol; 1971 May; 21(5):837-40. PubMed ID: 4930037
[TBL] [Abstract][Full Text] [Related]
18. A multicentre study of the in-vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens.
Amyes SG; Baird DR; Crook DW; Gillespie SH; Howard AJ; Oppenhiem BA; Pedler SJ; Paull A; Tompkins DS; Lawrie SA
J Antimicrob Chemother; 1994 Nov; 34(5):639-48. PubMed ID: 7706159
[TBL] [Abstract][Full Text] [Related]
19. Effect of some antibiotics on pigmentation in Serratia marcescens.
Anğ-Küçüker M; Büyükbaba-Boral O; Tolun V; Törümküney D; Susever S; Anğ O
Zentralbl Bakteriol; 2000 Jan; 289(8):781-5. PubMed ID: 10705609
[TBL] [Abstract][Full Text] [Related]
20. Detection of cefotaxime-resistant CTX-M-3 in clinical isolates of Serratia marcescens.
Tsou MF; Yu WL; Hung SW; Chi CJ; Chieh-Ju ; Chen SC; Wu LT
Folia Microbiol (Praha); 2004; 49(4):452-6. PubMed ID: 15530012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
